These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24828900)

  • 1. Modelling the natural history of primary progressive multiple sclerosis.
    Harding KE; Wardle M; Moore P; Tomassini V; Pickersgill T; Ben-Shlomo Y; Robertson NP
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):13-9. PubMed ID: 24828900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoking does not influence disability accumulation in primary progressive multiple sclerosis.
    Javizian O; Metz LM; Deighton S; Koch MW
    Eur J Neurol; 2017 Apr; 24(4):624-630. PubMed ID: 28239937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression rates and sample size estimates for PPMS based on the CLIMB study population.
    Raghavan K; Healy BC; Carruthers RL; Chitnis T
    Mult Scler; 2015 Feb; 21(2):180-8. PubMed ID: 25070676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary study of multiple sclerosis disability in South East Wales.
    Harding KE; Ingram G; Tallantyre EC; Joseph F; Wardle M; Pickersgill TP; Willis MD; Tomassini V; Pearson OR; Robertson NP
    J Neurol Neurosurg Psychiatry; 2023 Apr; 94(4):272-279. PubMed ID: 36328420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
    Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry.
    Braune S; Bluemich S; Bruns C; Dirks P; Hoffmann J; Heer Y; Rouzic EM; Bergmann A;
    BMC Neurol; 2023 Jul; 23(1):258. PubMed ID: 37407914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term disability progression of pediatric-onset multiple sclerosis.
    McKay KA; Hillert J; Manouchehrinia A
    Neurology; 2019 Jun; 92(24):e2764-e2773. PubMed ID: 31092624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.
    Rzepiński Ł; Zawadka-Kunikowska M; Maciejek Z; Newton JL; Zalewski P
    Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159275
    [No Abstract]   [Full Text] [Related]  

  • 17. Prospective study of multiple sclerosis with early onset.
    Ghezzi A; Pozzilli C; Liguori M; Marrosu MG; Milani N; Milanese C; Simone I; Zaffaroni M
    Mult Scler; 2002 Apr; 8(2):115-8. PubMed ID: 11990867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
    Stellmann JP; Neuhaus A; Lederer C; Daumer M; Heesen C
    PLoS One; 2014; 9(3):e92761. PubMed ID: 24651401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
    Portaccio E; Fonderico M; Iaffaldano P; Pastò L; Razzolini L; Bellinvia A; De Luca G; Ragonese P; Patti F; Brescia Morra V; Cocco E; Sola P; Inglese M; Lus G; Pozzilli C; Maimone D; Lugaresi A; Gazzola P; Comi G; Pesci I; Spitaleri D; Rezzonico M; Vianello M; Avolio C; Logullo FO; Granella F; Salvetti M; Zaffaroni M; Lucisano G; Filippi M; Trojano M; Amato MP;
    JAMA Neurol; 2022 Sep; 79(9):869-878. PubMed ID: 35877104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.